SavedAdd your journal

Journals / Sigma Mühendislik ve Fen Bilimleri Dergisi / 2017 / Cilt: 35 - Sayı: 2

FIGHTER MOLECULES AGAINIST TO CANCER – PEPTIDE VACCINES

Buket ERGİN
Pelin PELİT ARAYICI
Zeynep MUSTAFAEVA
Baxtiyar MAMEDOV
Pages
203–211
Publication Date
2017-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim is to destroy the tumour antigens by T lymphocytes which are activated by the immune system using peptide sequences.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cancer is one of the biggest disease of our age.
📊
Key Findings & Data:Chance of survival decreases as the diagnosis prolongs.
💡
Conclusion & Impact:The aim is to destroy the tumour antigens by T lymphocytes which are activated by the immune system using peptide sequences.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Cancer · peptide vaccine · carrier molecules

Abstract

Cancer is one of the biggest disease of our age. Chance of survival decreases as the diagnosis prolongs. Being an insidious disease makes it harder to determine and diagnose early for cancer. There are lots of studies about fighting this disease. In recent years, vaccine studies have gotten important to prevent cancer. Although cancer vaccine studies have a long history, studies which use peptide vaccines for cancer are applied about last 20 years. Peptide vaccines are created by using peptide sequences which generate the disease as template. The aim is to destroy the tumour antigens by T lymphocytes which are activated by the immune system using peptide sequences.

🔖

Cite This Article

ERGİN, B., ARAYICI, P. P., MUSTAFAEVA, Z., MAMEDOV, B. (2017). FIGHTER MOLECULES AGAINIST TO CANCER – PEPTIDE VACCINES. Sigma Mühendislik ve Fen Bilimleri Dergisi, Cilt: 35 - Sayı: 2, 203–211. https://ajindex.com/articles/418973

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Kutluk T., Kars A., (1992) General Information About Cancer, Turkish Cancer Research and War Foundation, Ankara, Turkey
  2. Çevik O., Aydın U., Gürsoy R.N., (2012) Lymphatic Targeting in Cancer Therapy, Hacettepe University Journal of the Faculty of Pharmacy 32, 1, 67–90
  3. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D., (2011) Global Cancer Statistics, CA: A Cancer Journal of Clinicans 61, 2, 69-90
  4. Yılmaz B.E., Health Directorate of Istanbul [Internet] Poole, Haydarpaşa Numune EAH Medical Oncology Unit, Available from: http://istanbulsaglik.gov.tr/w/sb/per/belge/kansere_genel.pdf, [accessed August 25, 2016]
  5. Gürdöl F., Ademoğlu E., (2006) Biochemistry, Nobel Medical Publishing, İstanbul, Turkey
  6. Kocagöz S., (2014) Technology and Types of Vaccine, Adult Vaccine Symposium (Erişkin aşı sempozyumu), 4 March 2014, İzmir, Turkey
  7. Anonim, Acıbadem System [Internet] Poole, Available from: http://www.acibadem.com.tr/Hayat/Bilgi/kanserle-savasta-yeni-bir-yontem-immunoterapi [accessed August 27, 2016]
  8. Anonim(2016), Available from: http://www.yesimeralp.com/kanser-ve-immunoterapi [accessed August 27, 2016]
  9. Restifo N.P., Dudley M.E., Rosenberg A.S., (2012) Adoptive Immunotheraphy for Cancer: Harnessing the T Cell Response, İstanbul University Journal of Science 12, 4, 269-81
  10. Omay SB., (2006) Immunotherapy in Neuro-Oncology, Journal of Turkish Neurosurgery, 16, 1, 23-24
  11. Wang R.F., Appella E., Kawakami Y., Kang X., Rosenberg S.A., (1996) Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes, J Exp Med 184,6, 2207–2216
  12. Ladjemi M.Z., Jacot W., Chardes T., Pelegrin A., NavarroTeulon I., (2010) Anti-HER2 Vaccines: New Prospects for Breast Cancer Therapy, Cancer Immunol Immunother 59, 9, 1295-312
  13. Cohen R.B., (2003) Epidermal Growth Factor Receptor as a Therapeutic Target in Colorectal Cancer, Clin Colorectal Cancer 2,4, 246–251
  14. Shadidi M., Sioud M., (2003) Selective Targeting of Cancer Cells Using Synthetic Peptides, Drug Resist Update 6, 6, 363-71
  15. Adessi C., Soto C., (2002) Converting a Peptide Into a Drug: Strategies to Improve Stability and Bioavailability, Curr Med Chem 9, 9, 963-78
  16. Sesardic D. J, (1993) Synthetic Peptide Vaccines, J. Med. Microbiol 39, 241-242
  17. Bijker M.S., Melief C.J., Offringa R., van der Burg S.H., (2007) Design and Development of Synthetic Peptide Vaccines: Past, Present and Future. Expert Rev. Vaccines 6, 4, 591-603. [18]